What oral hydromorphone dose is equivalent to 1.5 mg of intravenous Dilaudid (hydromorphone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Oral Hydromorphone Conversion from 1.5 mg IV Dilaudid

1.5 mg of intravenous (IV) Dilaudid (hydromorphone) converts to 7.5 mg of oral hydromorphone using the standard conversion factor of 5 (range 2.5-5) 1.

Conversion Calculation

The 2025 NCCN Adult Cancer Pain Guidelines provide explicit equianalgesic dosing in their opioid conversion table 1:

  • Parenteral (IV) hydromorphone: 1.5 mg
  • Oral hydromorphone: 7.5 mg
  • IV to PO conversion factor: 2.5-5

Using the direct conversion from the guideline table:

  • 1.5 mg IV hydromorphone = 7.5 mg oral hydromorphone

Important Clinical Considerations

When converting from IV to oral, reduce the calculated equianalgesic dose by 25-50% to account for incomplete cross-tolerance if the patient was well-controlled on the IV dose 2. However, if pain was inadequately controlled, you may use 100% of the equianalgesic dose or even increase by 25% 2.

Renal Function Caution

Hydromorphone should be used with extreme caution in patients with fluctuating renal function due to potential accumulation of renally cleared metabolites that can cause neurologic toxicity, including confusion, drowsiness, and hallucinations 1. In patients with moderate to severe renal dysfunction (eGFR <30 mL/min), fentanyl or buprenorphine are preferred alternatives 3, 4.

Dosing Schedule

  • Duration of action: 2-3 hours for immediate-release oral hydromorphone 1
  • Schedule around-the-clock dosing with breakthrough doses available
  • Breakthrough dose should be approximately 10% of total daily dose 5, 4

Alternative Conversion Pathways

If converting to other oral opioids instead of oral hydromorphone:

To oral morphine:

  • 1.5 mg IV hydromorphone → 10 mg IV morphine (using 1:6.67 ratio)
  • 10 mg IV morphine → 30 mg oral morphine (using 1:3 ratio)
  • Therefore: 1.5 mg IV hydromorphone ≈ 30 mg oral morphine

To oral oxycodone:

  • Using morphine equivalents: 30 mg oral morphine ≈ 15-20 mg oral oxycodone 1

Morphine Milligram Equivalents (MME)

For reference, 1.5 mg IV hydromorphone equals:

  • 7.5 MME (using the hydromorphone conversion factor of 5) 6, 7

This conversion is critical for monitoring total opioid burden and adhering to prescribing guidelines that recommend caution at ≥50 MME/day 7.

References

Guideline

adult cancer pain, version 2.2025, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2025

Guideline

adult cancer pain.

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.